Faricimab, Roche’s investigational bispecific antibody for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), has now been filed with the European Medicines Agency for review for potential pan-EU marketing authorization.
Roche Seeks EU Marketing Approval For Novel Eye Disease Drug Faricimab
Chugai Has Submitted The Japanese Filing
If approved, Roche’s bispecific antibody could become the first in a new class of medicines in years for treating macular degeneration and diabetic macular edema.
